Advance Immunotherapy 2.0 Presented at USA-Saudi Biotech Alliance Summit

In a significant move to enhance international collaboration in biotechnology, NantWorks, LLC, and ImmunityBio, Inc. announced the inaugural U.S.-Saudi Biotech Alliance Summit.

This high-level event, scheduled for January 14, 2026, will bring together prominent leaders from the United States and the Kingdom of Saudi Arabia (KSA) across various sectors, including government, healthcare delivery, biotechnology, advanced manufacturing, artificial intelligence, and finance.

The primary objective of Advance Immunotherapy 2.0 is to move from high-level discussions to concrete. These actionable partnerships accelerate the development, manufacturing, and global deployment of advanced immunotherapies and innovative healthcare technologies.

This collaboration builds on existing ties between ImmunityBio and Saudi entities, including a Memorandum of Understanding from 2025 aimed at introducing ImmunityBio's U.S. FDA-approved Cancer BioShield platform to the KSA and the broader Middle East.

The Summit comes at a crucial time for the global biotechnology landscape, particularly as ImmunityBio advances its pipeline of immunotherapies designed to activate both innate and adaptive immune responses against cancers and infectious diseases.

Designated an FDA Breakthrough Therapy, ANKTIVA®, plus BCG vaccine, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response.

To meet demand, a recombinant Bacillus Calmette-Guérin (rBCG) vaccine is also available in the USA.

As of 2026, Anktiva plus BCG Vaccine is approved in the KSA, Europe, and the UK and is available at various clinical sites and cancer centers in the U.S.

ImmunityBio is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. 

According to Don Hackett, Vax-Before-Travel.com's new publisher, 'this innovative initiative underscores the potential for enhanced U.S.-Saudi cooperation to drive innovation in AI-enabled biomanufacturing and to make accessible next-generation treatments. Furthermore, reduce the number of untreatable cancer cases.'

For more information about the Summit and ImmunityBio's ongoing work in immunotherapy, visit ImmunityBio.com.